Targeting tumor stromal cells through a PDGF-beta receptor binding carrier

Jai Prakash*, Edwin de Jong, Eduard Post, Ara K. Mohammad, Leonie Beljaars, Klaas Poelstra

*Corresponding author for this work

    Research output: Contribution to journalArticleAcademicpeer-review

    4 Citations (Scopus)


    Tumor stromal cells significantly contribute to tumor growth and abundantly express platelet-derived growth factor-beta receptor (PDGF-βR). In this study, we targeted stromal as well as tumor cells using our PDGF-βR binding carrier (pPB-HSA). pPB-HSA showed PDGF-βR-specific binding in-vitro and, in-vivo it rapidly accumulated in C26 tumors in mice after i.v. injection. We conjugated doxorubicin to pPB-HSA and, the conjugate showed antitumor effects in-vitro in tumor and stromal cells and in-vivo in C26-tumor bearing mice.
    Original languageEnglish
    Pages (from-to)e116
    JournalJournal of controlled release : official journal of the Controlled Release Society
    Issue number1
    Publication statusPublished - 20 Nov 2010


    Dive into the research topics of 'Targeting tumor stromal cells through a PDGF-beta receptor binding carrier'. Together they form a unique fingerprint.

    Cite this